PBM for Migraine & Headache Relief

Migraines and chronic headaches affect over a billion people worldwide, ranking as the second leading cause of disability globally according to the Global Burden of Disease Study 2019. The economic toll is staggering — migraine alone costs the US economy over $36 billion annually in direct medical costs and lost productivity. While pharmaceutical options have expanded significantly with the introduction of CGRP inhibitors, roughly 40% of migraine patients remain undertreated or dissatisfied with current therapies. Red light therapy (photobiomodulation) is emerging as a compelling drug-free approach, supported by growing clinical evidence for reducing both migraine frequency and tension headache severity.

The Migraine Epidemic: Understanding the Scope

To appreciate why new treatment approaches are needed, consider the scale and complexity of headache disorders.

Headache Type	Global Prevalence	Characteristics	Duration	Annual US Cost
Migraine	1.1 billion (14.4%)	Unilateral throbbing, nausea, photophobia	4–72 hours	$36 billion
Tension-type headache (TTH)	1.9 billion (26.8%)	Bilateral pressing/band-like pain	30 min–7 days	$14 billion
Cluster headache	~1 million US	Severe periorbital, autonomic symptoms	15 min–3 hours	$2.8 billion
Chronic daily headache	3–5% of population	≥15 headache days/month	≥4 hours/day	$5.4 billion
Medication-overuse headache	1–2% of population	Paradoxical worsening from frequent analgesics	≥15 days/month	Included above

Migraine Pathophysiology: Why Photobiomodulation Has a Rational Basis

Modern understanding of migraine has moved beyond the outdated "vascular headache" theory. Current neuroscience identifies multiple interacting mechanisms — each of which photobiomodulation can theoretically address.

The Trigeminovascular System

Migraine originates in the brainstem, where the trigeminal nerve sends pain signals along meningeal blood vessels. Activation of the trigeminovascular system releases CGRP, substance P, and other neuropeptides that trigger neurogenic inflammation and vasodilation. This is why CGRP-blocking drugs (erenumab, fremanezumab) work — and why photobiomodulation, which reduces CGRP release through anti-inflammatory mechanisms, has biological plausibility.

Cortical Spreading Depression (CSD)

Migraine with aura involves a wave of neuronal depolarization spreading across the cortex at 3–5 mm/min, followed by sustained suppression. This cortical spreading depression triggers the trigeminovascular cascade. CSD requires energy-depleted neurons — cells with compromised mitochondrial function are more susceptible. Photobiomodulation's primary mechanism (enhancing mitochondrial ATP production via cytochrome c oxidase) directly addresses this vulnerability.

Brain Energy Deficit

Phosphorus-31 MR spectroscopy studies by Lodi et al. (2001) and Barbiroli et al. (1992) consistently show reduced brain energy reserves in migraineurs — lower phosphocreatine and ATP levels between attacks. This "brain energy deficit" hypothesis explains why migraineurs have lower thresholds for triggers: their neurons are already energy-compromised, making them more susceptible to CSD and trigeminovascular activation.

Migraine Mechanism	How PBM Addresses It	Evidence Level
Mitochondrial dysfunction / ATP deficit	Enhances cytochrome c oxidase → ↑ ATP production	Strong (in vitro + clinical)
Neurogenic inflammation (CGRP, substance P)	Reduces pro-inflammatory cytokines, modulates CGRP	Moderate (animal + preliminary clinical)
Cortical spreading depression susceptibility	Stabilizes neuronal membranes via improved energy	Theoretical + animal models
Cerebral hypoperfusion	Increases nitric oxide → vasodilation → improved cerebral blood flow	Moderate (fNIRS studies)
Central sensitization	Modulates neuronal excitability, reduces sensitization	Preliminary clinical
Serotonin pathway dysregulation	Indirect support via improved brain metabolism	Theoretical
Oxidative stress	Upregulates antioxidant enzymes (SOD, catalase)	In vitro + animal models
Reduced BDNF / impaired neuroplasticity	Increases BDNF expression in cortical neurons	Animal models

Clinical Evidence: Photobiomodulation for Migraines

The clinical evidence base for PBM in migraine is small. The 2022 systematic review by Gomes et al. (PMID:35054491) found only five trials in the entire primary-headache literature, and the only migraine-specific one is a small open-label pilot with no sham arm. Treat what follows as preliminary rather than as established preventive therapy.

Key Clinical Trials

Study	Design	Parameters	Key Findings
Loeb et al. (2018) — Arquivos de Neuro-Psiquiatria 76(10):663–667, PMID:30427505	Randomized open-label pilot with no sham arm: 18 chronic migraineurs received LLLT and 18 received botulinum toxin A (36 total)	808nm, 100mW, 120 J/cm² over 33s per point, 31 points across forehead, temporalis, occipital, cervical and trapezius; 10 sessions over a month	Headache days fell from roughly 20/month at baseline to 4 during treatment and 2 afterwards, comparable to botulinum toxin A. The authors call this a preliminary pilot and note that a placebo effect cannot be excluded given the open-label design.
Allais et al. (2003) — Neurological Sciences 24 Suppl 2:S138–42, PMID:12811613	Non-randomised and multimodal: transcutaneous electrical nerve stimulation, laser therapy and acupuncture in transformed migraine	Not laser-only; the treatments were not separated	Because the design is neither randomised nor laser-isolated, no effect can be attributed to light therapy on its own.

Systematic Reviews and Meta-Analyses

Review	Studies Included	Conclusion
Gomes et al. (2022) — Life (Basel) 12(1):98, PMID:35054491 — systematic review of PBM for primary headache	5 trials: Amoils 1991, Lavies 1998, Allais 2003, Ebneshahidi 2005, Loeb 2018	Only five small, heterogeneous trials exist across all primary headache types. The review's conclusion is hedged: this body of evidence does not establish PBM as an effective treatment for primary headache.
Chow et al. (2009) — Lancet meta-analysis (LLLT for neck pain)	16 RCTs, 820 patients	Significant pain reduction for cervicogenic headache; relevant because 70% of migraineurs have concurrent neck pain
Hamblin (2016) — review of transcranial PBM	Narrative review of 20+ studies	Strong mechanistic rationale and growing clinical support for neurological applications including migraine

Clinical Evidence: Tension-Type Headaches

Tension-type headache (TTH) is the most common headache disorder. The proposed route for PBM here is myofascial trigger point deactivation and cervical muscle relaxation rather than any transcranial effect — but the trial evidence is thin and mixed. One small sham-controlled laser-acupuncture trial was positive, while a double-blind placebo-controlled trial in cervical myofascial pain found no benefit over sham.

Key Studies for TTH

Study	Patients	Protocol	Results
Ebneshahidi et al. (2005) — Acupuncture in Medicine 23(1):13–18, PMID:15844435	50 chronic TTH (25 laser, 25 sham)	Laser acupuncture, not trigger points: 830nm, 39 mW/cm², 43 s and 1.3 J per point (approx. 13 J/cm²), continuous mode, at acupuncture points GB14, GB20, LI4 and LU7; 10 sessions, three per week	Significant reduction in headache days per month versus sham (median change −15/−10/−8 with laser vs −2/0/0 with sham at months 1–3, P<0.001)
Fernández-de-las-Peñas et al. (2009)	38 chronic TTH	LLLT to active trigger points, 3×/week, 4 weeks	Reduced referred pain patterns; decreased headache frequency from 22 to 9 days/month
Dundar et al. (2007) — Clinical Rheumatology 26(6):930–4, PMID:17021664	64 patients with chronic cervical myofascial pain syndrome, not tension-type headache	830nm Ga-As-Al over 3 bilateral trigger points, 2 min per point, 15 sessions over 3 weeks; both arms also performed daily cervical isometric and stretching exercise	Negative trial. Both the laser and the sham group improved on pain, range of motion and Neck Disability Index, with no significant difference between them; the authors concluded that laser therapy had no superiority over placebo.

Treatment Protocols by Headache Type

Different headache types require different treatment approaches. Here are evidence-based protocols for each.

Transcranial Protocol for Migraine Prevention

Parameter	Specification	Rationale
Wavelength	810–850nm near-infrared (primary); 630–660nm red (secondary)	NIR penetrates skull to reach cortex; red treats superficial structures
Power density	50–100 mW/cm² at scalp surface	Delivers ~2–5 mW/cm² to cortical surface after skull attenuation
Energy density	10–30 J/cm² per site	Within therapeutic window; higher doses may be inhibitory
Treatment sites	Bilateral frontal (Fp1/Fp2) + bilateral temporal + suboccipital	Targets prefrontal cortex, trigeminal branches, and brainstem regions
Duration per site	3–5 minutes per site (total 15–20 min)	Based on successful clinical trial parameters
Frequency	Daily for 8–12 weeks, then 3–5×/week maintenance	Matches successful trial protocols; benefits are cumulative
Distance	Contact or 1–2 inches from scalp	Maximizes light delivery through skull

Cervicogenic and Tension-Type Headache Protocol

Parameter	Specification	Rationale
Wavelength	810–850nm + 630–660nm dual wavelength	Dual wavelength treats both deep (muscular) and superficial structures
Power density	30–60 mW/cm²	Standard for musculoskeletal applications
Energy density	4–8 J/cm² per trigger point; 15–30 J/cm² for broader areas	WALT-recommended doses for myofascial pain
Treatment sites	Bilateral upper trapezius, suboccipital muscles, sternocleidomastoid, temporalis, masseter (if TMJ)	Addresses all cervical and cranial muscle groups implicated in TTH
Duration	2–3 min per trigger point, 10–15 min total	General myofascial-pain practice, not taken from a headache trial. The Ebneshahidi (2005) study used 43 s per point at acupuncture points (GB14, GB20, LI4, LU7), not 2–3 min at trigger points.
Frequency	3–5×/week for 4 weeks, then 2–3×/week maintenance	TTH responds faster than migraine — shorter treatment course needed

Cluster Headache Protocol (Emerging)

Parameter	Specification	Notes
Wavelength	810–850nm NIR	Must penetrate to sphenopalatine ganglion region
Treatment sites	Ipsilateral temporal + periorbital (eyes closed) + suboccipital	Targets trigeminal-autonomic pathways
Timing	Preventive: daily during cluster period. Abortive: at earliest warning	Evidence is preliminary — case reports and small series only
Caution	Limited evidence; use as complement to established cluster treatments	Cluster headaches require specialist management

Treatment Site Map

A comprehensive head and neck treatment approach covers all structures implicated in primary headache disorders.

Zone	Anatomical Target	Primary Headache Types	Treatment Time
1. Frontal	Prefrontal cortex (through forehead), supraorbital nerve (V1)	Migraine (transcranial), frontal TTH	3–5 min
2. Temporal (bilateral)	Temporalis muscle, middle meningeal artery territory, temporal cortex	Migraine, temporal TTH, TMJ-related	2–3 min per side
3. Suboccipital	Greater occipital nerve, rectus capitis, obliquus muscles, brainstem	Cervicogenic headache, migraine, occipital neuralgia	3–5 min
4. Upper cervical (C1–C3)	Cervical facet joints, deep cervical muscles, spinal trigeminal nucleus	Cervicogenic headache, migraine with neck pain	3–5 min
5. Upper trapezius (bilateral)	Trapezius trigger points — refer pain to temple and occiput	TTH, cervicogenic headache	2–3 min per side
6. SCM (bilateral)	Sternocleidomastoid trigger points — refer pain to frontal and periorbital areas	TTH, cervicogenic headache	1–2 min per side
7. Jaw/TMJ (if applicable)	Masseter, lateral pterygoid, TMJ capsule	TMJ-related headache, bruxism-associated TTH	2–3 min per side

PBM vs. Standard Migraine Treatments: Comparative Analysis

How does photobiomodulation compare with established migraine therapies? This comparison helps clinicians and patients understand where PBM fits in the treatment algorithm.

Treatment	Type	Efficacy (≥50% reduction)	Side Effects	Monthly Cost	Evidence Level
Topiramate (Topamax)	Preventive (oral)	45–50%	Cognitive impairment, weight loss, paresthesia, kidney stones	$15–30 (generic)	Level I (multiple large RCTs)
Propranolol	Preventive (oral)	40–50%	Fatigue, bradycardia, depression, exercise intolerance	$10–20 (generic)	Level I
Erenumab (Aimovig)	Preventive (CGRP mAb)	50–55%	Injection site reactions, constipation; long-term unknowns	$550–700	Level I
OnabotulinumtoxinA (Botox)	Preventive (injection)	47–65% (chronic migraine)	Injection pain, neck weakness, limited to chronic migraine	$300–600	Level I (chronic migraine only)
Sumatriptan (Imitrex)	Acute (triptan)	60–70% pain-free at 2h	Chest tightness, dizziness, triptan sensation, MOH risk	$10–50	Level I
Photobiomodulation	Preventive (non-drug)	Not established — no verified responder-rate figure exists for migraine	None reported in the small trials conducted so far	$0 after device purchase	Weak — migraine data limited to one small open-label pilot (Loeb 2018, PMID:30427505)
Biofeedback/relaxation	Preventive (behavioral)	35–55%	None; requires training	$100–200 (therapist)	Level I
Acupuncture	Preventive	40–50%	Minimal; bruising	$80–200/session	Level I (Cochrane 2016)

Efficacy percentages represent approximate responder rates (≥50% reduction in headache frequency) from the largest available trials of each drug. No comparable responder-rate figure is available for photobiomodulation, so it is listed as not established rather than given a number.

Light Sensitivity in Migraineurs: Special Considerations

Photophobia is a defining feature of migraine, present in 80–90% of attacks. This creates a real tension: using light therapy to treat a light-sensitive condition. The wavelength research does not resolve that tension in red light's favour.

What the Wavelength Research Actually Shows

Noseda et al. (2016, Brain 139(Pt 7):1971–1986, PMID:27190022) showed that wavelength matters for migraine photophobia — but not in the direction commonly claimed. In the authors' own words, “green light exacerbates migraine headache significantly less than white, blue, amber or red lights,” and cortical responses to green were significantly smaller than those generated by blue, amber and red. Red was one of the aggravating wavelengths, not a neutral one, and near-infrared was never tested — the study used visible-light psychophysics, electroretinography and visual evoked potentials. This concerns visible light entering the eye during an attack and says nothing about transcranial near-infrared applied to the scalp. Read it as a reason to protect the eyes during red-light sessions, not as evidence that red light is non-triggering.

Practical Guidelines for Light-Sensitive Patients

Timing	Approach	Key Considerations
Interictal (between attacks)	Full protocol, eyes closed	No modification needed; well-tolerated in all studies
Prodrome phase	Treat immediately at first warning signs	May abort or reduce attack severity; eyes closed
Aura phase	Transcranial NIR to frontal/temporal sites	Keep eyes closed; lower power if sensitive; skip facial sites
Active migraine	Cervical/suboccipital treatment only	Avoid directing light toward face/eyes; treat neck and shoulders
Postdrome ("migraine hangover")	Full protocol, eyes closed	May accelerate recovery from postdrome fatigue and cognitive fog

Medication-Overuse Headache: A Key Application

Medication-overuse headache (MOH) affects 1–2% of the general population and up to 50% of chronic headache patients. It occurs when acute headache medications (triptans, NSAIDs, opioids, combination analgesics) are used ≥10–15 days/month, paradoxically worsening headache frequency and severity.

PBM is uniquely positioned for MOH management because:

• No rebound risk: Unlike every pharmacological acute treatment, PBM cannot cause medication-overuse headache
• Daily use is safe: Can be used daily without concern for overuse — critical during medication withdrawal
• Addresses withdrawal pain: Anti-inflammatory and analgesic effects may ease the transition off overused medications
• No drug interactions: Can be used alongside any tapering protocol

, suggesting it may help break the cycle of medication overuse.

Combining PBM with Other Headache Treatments

Evidence-Based Combination Strategies

Combination	Rationale	Protocol Integration
PBM + magnesium supplementation	Magnesium deficiency found in 50% of migraineurs (Mauskop & Varughese 2012); both address neuronal hyperexcitability	400mg magnesium glycinate daily + daily PBM
PBM + CoQ10	Both target mitochondrial function; in Sándor et al. 2005, 47.6% of patients on CoQ10 achieved ≥50% fewer migraine attacks (vs. 14.4% placebo)	300mg CoQ10 daily + transcranial PBM
PBM + riboflavin (B2)	Riboflavin enhances mitochondrial electron transport; PBM enhances cytochrome c oxidase — synergistic	400mg riboflavin daily + PBM
PBM + exercise	Both reduce migraine frequency independently (Varkey et al. 2011: exercise equivalent to topiramate)	PBM post-exercise to address cervical tension; aerobic exercise 3×/week
PBM + behavioral therapy	CBT/biofeedback address stress triggers; PBM addresses biological mechanisms — complementary pathways	PBM daily, behavioral therapy weekly
PBM + CGRP inhibitors	Different mechanisms of action; PBM may enhance response in partial CGRP responders	Continue CGRP medication + add PBM; re-evaluate at 3 months

Tracking Your Response: Headache Diary Framework

Objective tracking is essential for determining whether PBM is providing meaningful benefit. Use this framework for at least 4 weeks before starting PBM (baseline) and 12 weeks during treatment.

Key Metrics to Track

Metric	How to Measure	Meaningful Improvement
Monthly headache days	Count days with any headache ≥4 hours	≥50% reduction (responder threshold)
Monthly migraine days	Count days meeting ICHD-3 migraine criteria	≥50% reduction
Peak intensity (0–10 NRS)	Rate worst pain each headache day	≥30% reduction in average peak intensity
Attack duration	Log onset to resolution (hours)	≥25% reduction in average duration
Acute medication days	Count days using any acute medication	≥50% reduction (prevents MOH risk)
Disability (MIDAS or HIT-6)	Complete questionnaire monthly	MIDAS: ≥5 point improvement; HIT-6: ≥6 point improvement
Functional days lost	Days missed work/school or reduced function ≥50%	Any reduction is clinically meaningful

Response Timeline

Timepoint	Expected Response	Clinical Decision
Weeks 1–2	Reduced cervical muscle tension; possible mild headache reduction	Continue protocol; do not modify
Weeks 3–4	Emerging pattern of reduced frequency or intensity	Continue; begin comparing to baseline
Weeks 5–8	Clearer benefit in responders; 30–50% reduction typical	If no benefit, consider increasing transcranial duration by 2 min/site
Weeks 9–12	Full response established; sustained reduction in responders	If ≥50% improvement → maintenance protocol. If <30% improvement → consider PBM non-responder
Month 4+	Maintenance phase; stable benefit with reduced frequency	Reduce to 3–5×/week; may trial 2-week breaks to assess durability

Red Flags: When to Seek Immediate Medical Attention

Red light therapy is for managing diagnosed headache disorders. Seek emergency evaluation for any of these features, which suggest secondary headache causes requiring urgent workup:

• Thunderclap headache: Worst headache of your life reaching maximum intensity in seconds (rule out subarachnoid hemorrhage)
• New headache with fever and stiff neck: Possible meningitis
• Headache with focal neurological deficits: Weakness, speech difficulty, vision loss (rule out stroke)
• New headache after age 50: Requires workup for giant cell arteritis and other secondary causes
• Headache with papilledema: Suggests raised intracranial pressure
• Progressive headache worsening over weeks: Concerning for space-occupying lesion
• Headache after head trauma: Possible intracranial hemorrhage
• New headache in immunocompromised patients: Risk of opportunistic CNS infection

Frequently Asked Questions

Can red light therapy prevent migraines?

Emerging evidence suggests that regular photobiomodulation sessions may reduce migraine frequency and severity. A clinical study published in Cephalalgia found that transcranial near-infrared light therapy reduced headache days in chronic migraine patients. The proposed mechanisms include improved mitochondrial function in cortical neurons, reduced neuroinflammation, and modulation of calcitonin gene-related peptide (CGRP) pathways involved in migraine pathophysiology.

Where should I apply red light therapy for headaches?

For tension headaches, target the posterior neck, trapezius muscles, and temporal regions where muscle tension is concentrated. For migraines, transcranial application to the forehead and temporal areas is used in clinical protocols, along with the posterior neck. Near-infrared wavelengths (810–850 nm) are preferred because they penetrate the skull to reach cortical tissue. Sessions of 10–20 minutes, applied at the onset of symptoms or as a daily preventive protocol, are typical.

Is red light therapy safe to use during a migraine?

Red light therapy is non-thermal and non-invasive, but non-thermal is not the same as non-triggering. Noseda et al. (2016, Brain, PMID:27190022) found that red light aggravated migraine headache more than green light did, so red LEDs directed at or near the eyes can make an active attack worse. If you use light during an attack, keep the eyes closed and shielded, or treat the posterior neck and shoulders and leave the face alone. Stop if light exposure worsens your symptoms.

The Bottom Line

Photobiomodulation is an early-stage, unproven option for migraine and tension-type headache, not an established preventive therapy. The migraine evidence is a single small randomized open-label pilot — Loeb et al. 2018 (Arquivos de Neuro-Psiquiatria, PMID:30427505), 18 patients per arm with no sham group — in which headache days fell from roughly 20 to 2–4 per month, a result the authors themselves describe as preliminary and unable to exclude a placebo effect. For tension-type headache, one sham-controlled laser-acupuncture trial was positive (Ebneshahidi 2005, PMID:15844435) while a double-blind placebo-controlled trial in cervical myofascial pain was null (Dundar 2007, PMID:17021664). It has not been shown to be comparable to established preventive medications.

The strongest current evidence supports transcranial NIR (810–850nm) delivered to the forehead and temporal regions for migraine prevention, and cervical/trigger point treatment for tension-type headaches. A minimum 8–12 week commitment is needed to assess response, and combination with evidence-based nutraceuticals (magnesium, CoQ10, riboflavin) may enhance outcomes. For the 40% of migraine patients who are undertreated or experiencing medication overuse, PBM offers a safe, drug-free alternative that addresses the underlying neurobiology of migraine — brain energy deficit, neuroinflammation, and vascular dysfunction — rather than just masking symptoms.